BioNTech SE (BVMF:B1NT34)

Brazil flag Brazil · Delayed Price · Currency is BRL
32.19
+0.09 (0.28%)
At close: Dec 3, 2025
-27.60%
Market Cap123.35B
Revenue (ttm)19.71B
Net Income (ttm)-3.57B
Shares Outn/a
EPS (ttm)-14.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume120
Average Volume1,107
Open32.25
Previous Close32.10
Day's Range31.98 - 32.25
52-Week Range30.80 - 49.05
Beta1.31
RSI39.14
Earnings DateMar 10, 2026

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6,772
Stock Exchange Brazil Stock Exchange
Ticker Symbol B1NT34
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.